美股A股
StockGist
Back
10-Q2026-05-06· qwen-plus

RXST · RxSight, Inc.

0001193125-26-208921

SEC filing

Summary

Revenue declined 18.5% to $30.9M and net loss widened 93.9% to $15.9M, driven primarily by lower LDD unit volumes — the capital equipment foundation for the company’s Light Adjustable Lens platform.

Key takeaways

Full analysis

Revenue decreased 18.5% year-over-year to $30.9 million, a decline explicitly attributed in the filing to lower LDD unit volumes. The LDD is the capital equipment device required for use of the Light Adjustable Lens (LAL), and its sale involves significant upfront investment by ophthalmic practices. Because LDD placements anchor the entire revenue ecosystem — enabling subsequent LAL consumables, calibration services, and software upgrades — volume contraction directly constrains the downstream growth engine. This dynamic also explains why gross margin remained stable at 76.1%: the decline was not due to discounting or unfavorable product mix, but rather to reduced volume in the highest-margin hardware segment, with LAL consumables likely contracting proportionally.

Operating income declined 67.0% to -$17.8 million, reflecting the challenge of aligning fixed commercial costs with falling revenue. As noted in the Risk Factors, the company faces risk if efforts to expand and train its sales force do not generate corresponding revenue increases — or if it cannot reduce costs in response to unexpected demand declines. The widening loss indicates that commercial infrastructure investments remained largely in place despite lower LDD placements, underscoring structural cost inflexibility in the near term.

Net cash used in operating activities increased to -$10.9 million, signaling deteriorating working capital efficiency. While the filing does not quantify inventory changes, it acknowledges operational reliance on demand forecasting to manage third-party manufacturing and supplier orders — a process vulnerable to forecast error during periods of volatility. A decline in sales combined with forward-looking inventory planning may have contributed to cash outflow pressure.

The commercial restructuring — unifying LAL sales and clinical support into a Customer Success Organization — represents a strategic pivot toward maximizing lifetime value per installed LDD base. This shift prioritizes retention, utilization, and expansion within existing accounts over new-account acquisition, acknowledging the capital intensity and extended sales cycle of LDD adoption. The timing of Scott Gaines’ transition from Chief Customer Officer to consultant on May 5, 2026 — immediately following quarter-end — reinforces this recalibration, aligning leadership structure with the renewed emphasis on customer success and long-term platform adoption rather than pure placement growth.